Joseph Gray’s Post

CVS Health is entering the business of selling private label biosimilar products with significant repercussions for biosimilar manufacturers. Last year, CVS Health launched Cordavis in an effort to partner with manufacturers to commercialize biosimilar drugs in the backdrop of several long-awaited Humira biosimilar launches. As its first partnership, Cordavis collaborated with Sandoz to commercialize Hyrimoz under a Cordavis private label. In addition, on April 2024, CVS Health removed Humira from its Advanced Control Specialty Formulary and added Hyrimoz as the preferred adalimumab product. The preferred options in the CVS Health Advanced control Specialty Formulary for 2024 are the high-WAC Hyrimoz from Sandoz, the low-WAC private label Hyrimoz from Cordavis, and the low-WAC unbranded adalimumab-adaz from Sandoz. The approach is driving a significant increase in new patient prescriptions for Hyremoz although Humira still retains the lion’s share of the market for existing patients.  The collaboration with Sandoz is likely the first of several efforts by CVS Health and other PBMs to penetrate the biosimilar market. In the coming years, several high-profile specialty brands will face LOE as key patent expirations materialize. These specialty brands represents a massive opportunity for CVS Health and other PBMs in a biosimilar market that is projected to grow to over $100B by 2029.  By establishing Cordavis, CVS sets the stage to compete directly with biosimilar and innovator products in the very marketplace it manages. The move grants CVS Health several advantages, including: - Higher margins: Store brands generally offer higher margins. In this case, it provides CVS the opportunity to share the biosimilar manufacturer’s profit margin - Greater negotiating power: A private label biosimilar provides CVS additional negotiating leverage with manufacturers of biosimilar and innovator products by strengthening CVS Health’s ability to access the product and secure favorable pricing - Patient loyalty and brand management: The move drives customer loyalty and builds the CVS Health brand while simultaneously promoting Sandoz’s product through the comparatively more established CVS brand  Biosimilar manufacturers will need to recalibrate their launch strategy to anticipate direct competition from PBMs marketing private label biosimilar products. Manufacturers can begin to navigate these dynamics by assessing the risk of white label competition from PBMs, developing strategic partnerships with PBMs and other stakeholders, getting crystal clear on their value proposition to payers. 

Introducing Krishna Medical Agency: Founded in 2020 and Thriving as Your Partner in Pharmaceutical Wholesale Distribution   Established in 2020, Krishna Medical Agency has rapidly emerged as a leading player in the wholesale distribution of pharmaceutical products. Committed to enhancing healthcare accessibility, we specialize in providing top-quality generic and over-the-counter (OTC) medical products, continually expanding our presence and impact in the industry.   Our Journey   Since our founding in 2020, Krishna Medical Agency has demonstrated a remarkable growth trajectory. We are driven by a vision to improve healthcare access, and our dedicated team of professionals has harnessed their extensive knowledge of the pharmaceutical landscape to help us evolve into a reliable name in the industry.   Our Offerings  Comprehensive Product Range: Our extensive product portfolio encompasses generic and OTC pharmaceuticals, addressing diverse medical needs. This includes prescription medications, dietary supplements, medical devices, and more.   Quality Assurance: Our unwavering commitment to quality ensures that every product we distribute undergoes rigorous quality control measures, guaranteeing the delivery of safe and effective pharmaceuticals to end-users.   Timely Delivery: Recognizing the importance of timely access to healthcare products, our efficient logistics and distribution network ensures your orders are delivered promptly.   Competitive Pricing: We are committed to affordability in healthcare. Our competitive pricing structures ensure that quality pharmaceutical products are within reach for a wide range of healthcare providers and retailers.   Why Choose Krishna Medical Agency   Reliability: Built on trust and consistency, our reputation means you can depend on us to fulfill your pharmaceutical needs reliably.   Customer-Centric Approach: Your success is our success. We value our customers and customize our services to meet your specific requirements.   Compliance: We adhere to all regulatory standards and guidelines, ensuring the highest level of compliance in our operations.   Innovation: Staying abreast of industry trends and innovations, we provide the latest and most relevant pharmaceutical products. Get in Touch  Founded in 2020, Krishna Medical Agency continues to be a dynamic force in the pharmaceutical distribution landscape. Whether you are a healthcare provider, pharmacy, or retailer, we invite you to partner with us to create a healthier and brighter future.  Contact us today to explore our product range, discuss your specific requirements, and discover how Krishna Medical Agency can be your trusted source for pharmaceutical distribution. Together, we can make healthcare accessible and effective for all. Experience excellence in pharmaceutical distribution with Krishna Medical Agency, where health is our commitment, and your success is our satisfaction.

Dual brand pharmaceuticals - gaming or fair game? Last week Charles River Associates released a brief report on the ins and outs of dual brand pharmaceuticals: Active ingredients registered and sold under different brands for different populations/indications. This is different from multi-indication use, classically such as adalimumab initially approved for rheumatoid arthritis and subsequently expanded to treat many other conditions, but with no variation to the product or brand supplied. A topical example is semaglutide, marketed as Ozempic for type 2 diabetes, and Wegovy for weight loss. The molecule is delivered in self-administered prefilled pens but with different dosages, reflecting the different therapeutic profiles needed, and different prices. Proponents argue dual branding is appropriate when there are substantial differences in patient populations, unmet need and value to patients/payers, where additionally product characteristics (dose, route of administration, formulation, site of care, role in regimen, etc. ) are different. In their report, CRA finds that payers support dual branding when there is "a strong rationale beyond just a difference in indication, which drives the differences in dosing, formulation, or ROA [route of administration], to justify a dual-brand approach". This is in contrast to simple dosage variations. When there are concrete and quantifiable differences in therapeutic profile, realised by studying additional patient groups, dual branding appears to be an appropriate commercial strategy supported by payers. But manufacturers will struggle to use dual branding as a simple ever-greening tactic. Full report linked below, with additional therapeutic area case studies 👇

Pure Theophylline Powder(API) CAS: 58-55-9 Molecular Formula: C7H8N4O2 Molecular Weight (g/mol): 180.17 MDL Number: MFCD00079619 InChI Key: ZFXYFBGIUFBOJW-UHFFFAOYSA-NShow More Synonym: theophylline, 1,3-dimethylxanthine, Elixophyllin, theophyllin, theolair, nuelin, theophylline anhydrous, respbid, theocin, theo-durShow More PubChem CID:2153 ChEBI: CHEBI:28177 IUPAC Name: 1,3-dimethyl-7H-purine-2,6-dione SMILES: CN1C2=C(C(=O)N(C1=O)C)NC=N2 Pure theophylline powder(API) refers to the active pharmaceutical ingredient theophylline in its pure, powdered form. Theophylline is a medication used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases. It works by relaxing the muscles in the lungs and chest, making it easier to breathe. The pure powder form of theophylline is the active component used in pharmaceutical preparations. https://lnkd.in/g6EeBScb

Pfizer has just done something incredible - it’s now selling some of its medicines direct-to-consumer. This is long overdue in the pharma industry. In many ways, this is excellent news! The news is part of a larger industry push to cut out middlemen and simplify the distribution of products. This will cut costs significantly and make it much easier for people to get the medication they need without jumping through hoops. Pfizer’s website will connect patients with consultants to prescribe the drugs and then a supplier who will fill and ship the prescriptions. The plan is to sell products like its COVID treatment, Paxlovid, and its migraine nasal spray. If you want to innovate, you need to do things differently, and I think this is both a bold and clever move by Pfizer.

Navigating the Rx (prescription drugs) and OTC (over-the-counter) drugs: Advertising Landscape As an advertising agency, we embrace unique challenges in crafting captivating campaigns for both Rx (prescription drugs) and OTC (over-the-counter) drugs. Let's dive into the fascinating world of pharmaceuticals and the diverse customer focus it demands. Rx vs. OTC: The Distinction A. Rx drugs require a doctor's prescription, while OTC drugs are for self-medication. B. OTC drugs are found in supermarkets, while Rx drugs are exclusive to pharmacies. C. Some drugs have dual roles, with slight variations in formulation, sold as OTC or Rx based on context. We always look for the OTC Opportunity. Working on OTC brands brings sheer delight! The generous budgets and broad target markets give us the creative freedom to soar high. Crafting campaigns for OTC drugs allows us to connect with diverse audiences and make a meaningful impact on their lives. However the Real deal is in unlocking the Rx Challenge. No honestly, the real art lies in mastering Rx drug campaigns, where intricacies abound. Navigating medical information, adhering to regulations, and targeting niche markets demand finesse that excites us. Building trust with healthcare professionals and patients is our ultimate goal. We value your perspective! When it comes to advertising, what captivates you more? The exhilarating freedom of OTC campaigns or the allure of mastering complexities in Rx drug promotion? Share your views below and let's ignite a stimulating conversation! #Advertising #Rx #OTC #Pharma #Creativity #Campaigns #Healthcare #Marketing #CustomerFocus #TargetAudience #Innovation #Pharmaceuticals #BrandPromotion #Engagement #CampaignCrafting #MedicalMarketing #RxvsOTC #health #Medicine Jyoti Shiralee Shantaprasad Nagarmath Rohit Nandkeshwar Archis Joshi Raja MVSMA Amey Dharashivkar Shivani Rane Goldie Yavari - Online/Live NAPLEX COURSES Dr Sudhakar Gayakwad @Dinesh Ghosalkar Ankit Sanklesha GnSadverting Gargi Sahasrabudhe Vivek Raina Ananta Thusu Pinkesh Jain

Pure #Theophylline Powder(API) CAS: 58-55-9 Molecular Formula: C7H8N4O2 Molecular Weight (g/mol): 180.17 MDL Number: MFCD00079619 InChI Key: ZFXYFBGIUFBOJW-UHFFFAOYSA-NShow More Synonym: theophylline, 1,3-dimethylxanthine, Elixophyllin, theophyllin, theolair, nuelin, theophylline anhydrous, respbid, theocin, theo-durShow More PubChem CID:2153 ChEBI: CHEBI:28177 IUPAC Name: 1,3-dimethyl-7H-purine-2,6-dione SMILES: CN1C2=C(C(=O)N(C1=O)C)NC=N2 Pure #theophylline powder(API) refers to the active pharmaceutical ingredient theophylline in its pure, powdered form. Theophylline is a medication used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases. It works by relaxing the muscles in the lungs and chest, making it easier to breathe. The pure powder form of theophylline is the active component used in pharmaceutical preparations. https://lnkd.in/g6EeBScb

Therapeutic Goods Administration have updated their guidance on advertising cosmetic injectables to ensure advertising rules are applied consistently across all industries that deal with therapeutic goods. Recently, the TGA has observed that clinics and health services in other industry areas are advertising the availability of prescription medicines, usually by referring to a class of goods (for example ‘weight loss injections’, ‘medicinal cannabis’ or ‘nicotine vaping products’). The TGA has interpreted that promoting a health service in this way is also an advertisement for a therapeutic good that refers to prescription medicines, which is unlawful. To resolve any inconsistency in interpretation across industry areas, the TGA no longer permits references to terms such as ‘wrinkle reducing injections’ where those terms would result in a reasonable consumer understanding the intention of the content is to promote the use or supply of a prescription medicine. The revised guidance on advertising #cosmetic injectables is now available on the TGA website. This material reinforces that the legislation itself regarding cosmetic injectables has not changed, and advertising the use or supply of prescription medicines, including most cosmetic injectable products (as opposed to services), has never been compliant with the therapeutic goods framework. This includes through use of testimonials, claims about the goods, before and after photos, or price lists. Read more: https://lnkd.in/gACDztTj

Keeping up with changes in a dynamic ever changing market can be a huge challenge for pharmaceutical sales teams.    Static segmentation models are not adaptive enough within this environment.   Dynamic segmentation provides a continuous process that enables sales teams to adapt their approaches to the changing needs of the market and its prescribers.   Read more about how dynamic segmentation gives you the agility you need to optimize your sales team effectiveness. Want to learn more? Let’s chat. #nextbestaction #dynamicsegmentation #pharmasales #pharma

Interesting article on big pharma dynamics. #bigpharma #pharmaceuticalindustry #novonordisk #elililly